News
A group of Victorian mothers have written to the health minister after struggling to get their children an antibody ...
The Centers for Disease Control and Prevention's vaccine advisory committee wrapped up the first day of its meeting since ...
7d
MedPage Today on MSNKennedy's ACIP Backs Monoclonal Antibody for RSV Prevention in InfantsThe CDC's newly reconstituted Advisory Committee on Immunization Practices (ACIP) voted 5-2 in support of infants younger ...
The ACIP is recommending the use of Enflonsia for the prevention of RSV lower respiratory tract disease in infants younger than 8 months.
The WA Department of Health has sent an urgent reminder to medical staff to make sure they’re giving patients the right RSV ...
The FDA delivered two notable approvals for RSV immunization, UroGen overcame a negative advisory committee vote to secure an ...
21hon MSN
Medical staff in Western Australia have been warned after reports of the wrong immunisations being given to patients.
Opinion
The economics of prevention: How maternal RSV immunisation can strengthen public health systemsWhile respiratory syncytial virus (RSV) typically causes mild symptoms in adults, the virus can be life-threatening for infants. The seasonal virus is the most common cause of lower respiratory tract ...
The vote offers a sigh of relief to doctors and public health experts worried about vaccine skepticism creeping into policymaking.
Respiratory syncytial virus (RSV) is a leading cause of acute lower respiratory infections (ALRTIs) in children under five and poses a persistent threat to child health worldwide.
The recommendation for Enflonsia is indicated for respiratory syncytial virus prevention in infants under eight months of age, expanding protection options ahead of the 2025–2026 season.
Some results have been hidden because they may be inaccessible to you
Show inaccessible results